메뉴 건너뛰기
Trends in Biotechnology
Volumn 18, Issue 9, 2000, Pages 364-369
New biopharmaceuticals in the USA: Trends in development and marketing approvals 1995-1999
Author keywords

[No Author keywords available]
Indexed keywords

ALPHAN1 INTERFERON; BECAPLERMIN; BETA1A INTERFERON; CONSENSUS INTERFERON; ETANERCEPT; FOMIVIRSEN; GLUCAGON; INFLIXIMAB; INSULIN LISPRO; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEPIRUDIN; LYME DISEASE VACCINE; PALIVIZUMAB; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT FOLLITROPIN; RECOMBINANT GLUCAGON; RECOMBINANT INTERLEUKIN 11; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RETEPLASE; RITUXIMAB; THYMOCYTE ANTIBODY; TRASTUZUMAB;
EID: 0034283885     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(00)01473-6     Document Type: Review
Times cited : (39)
References (8)
  • 1
    • 0029851022 scopus 로고    scopus 로고
    • First biopharmaceuticals approved in the U.S.: 1980-1994
    • Gosse, M.E. and Manocchia, M. (1996) First biopharmaceuticals approved in the U.S.: 1980-1994. Drug Inf. J. 30, 991-1001
    • (1996) Drug Inf. J. , vol.30 , pp. 991-1001
    • Gosse, M.E.1    Manocchia, M.2
  • 2
    • 85031613315 scopus 로고    scopus 로고
    • Prescription Drug User Fee Act of 1992. US Public Law 102-571 (1992 Oct 29); 21 USC 379; 106 Stat 4491
    • Prescription Drug User Fee Act of 1992. US Public Law 102-571 (1992 Oct 29); 21 USC 379; 106 Stat 4491
  • 3
    • 85031598872 scopus 로고    scopus 로고
    • Food and Drug Administration Modernization Act of 1997. US Public Law 105-115 (1997 Nov 21); 21 USC 355a; 111 Stat 2296
    • Food and Drug Administration Modernization Act of 1997. US Public Law 105-115 (1997 Nov 21); 21 USC 355a; 111 Stat 2296
  • 4
    • 85031604764 scopus 로고    scopus 로고
    • Fourth Annual Performance Report: Prescription Drug User Fee Act of 1992. FY 1996 Performance Report to Congress (Dec 1996), US Food and Drug Administration, Rockville, MD, USA
    • Fourth Annual Performance Report: Prescription Drug User Fee Act of 1992. FY 1996 Performance Report to Congress (Dec 1996), US Food and Drug Administration, Rockville, MD, USA
  • 5
    • 85031607612 scopus 로고    scopus 로고
    • Final Performance Report: Prescription Drug User Fee Act of 1992. Fiscal Year 1997 Report to Congress (Dec 1997), US Food and Drug Administration, Rockville, MD, USA
    • Final Performance Report: Prescription Drug User Fee Act of 1992. Fiscal Year 1997 Report to Congress (Dec 1997), US Food and Drug Administration, Rockville, MD, USA
  • 6
    • 85031613961 scopus 로고    scopus 로고
    • FY 1998 Performance Report to Congress for the Prescription Drug User Fee Act of 1992 as Amended by the Food and Drug Administration Modernization Act of 1997, US Food and Drug Administration, Rockville, MD, USA
    • FY 1998 Performance Report to Congress for the Prescription Drug User Fee Act of 1992 as Amended by the Food and Drug Administration Modernization Act of 1997, US Food and Drug Administration, Rockville, MD, USA
  • 7
    • 85031608764 scopus 로고    scopus 로고
    • FY 1999 Performance Report to Congress for the Prescription Drug User Fee Act of 1992 as Reauthorized and Amended by the Food and Drug Administration Modernization Act of 1997, US Food and Drug Administration, Rockville, MD, USA
    • FY 1999 Performance Report to Congress for the Prescription Drug User Fee Act of 1992 as Reauthorized and Amended by the Food and Drug Administration Modernization Act of 1997, US Food and Drug Administration, Rockville, MD, USA
  • 8
    • 0034045314 scopus 로고    scopus 로고
    • The new drug approvals of 1996, 1997 and 1998: Drug development trends in the user fee era
    • Kaitin, K.I. and Healy, E.M. (2000) The new drug approvals of 1996, 1997 and 1998: drug development trends in the user fee era. Drug Inf. J. 34, 1-14
    • (2000) Drug Inf. J. , vol.34 , pp. 1-14
    • Kaitin, K.I.1    Healy, E.M.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.